High-dose Vorinostat effective at treating relapsed lymphomasHutchinson Center A Life of SciencePreclinical studies at Fred Hutch and other research centers have found Vorinostat to be effective when used along with the standard chemotherapy combo, whi…
High-dose Vorinostat effective at treating relapsed lymphomasMedical XpressPreclinical studies at Fred Hutch and other research centers have found Vorinostat to be effective when used along with the standard chemotherapy combo, which is known by the ac…
Clinical Notes: HCV, Interferon, and HedgehogsMedPage TodayA drug with a mechanism of action similar to rituximab (Rituxan) but that may be more effective met its primary endpoint in the first part of a phase III trial, said its manufacturer. Compared …
|
In dirittura d’arrivo molte nuove molecole
Corriere della Sera È un anticorpo monoclonale anche ocrelizumab (Roche), al momento in fase 3 della sperimentazione: le procedure di registrazione dovrebbero arrivare nel 2015, quando è atteso anche l’arrivo di daclizumab HYP (anticorpo monoclonale in formulazione … |
|
Roche’s obinutuzumab significantly improves PFS in chronic lymphocytic leukemia
The Pharma Letter … with its investigational cancer drug obinutuzumab met its primary endpoint and an additional futility analysis suggested that it could show superiority compared to the company’s currently marketed MabThera/Rituxan (rituximab) in first line chronic … |
|
US biotechs “lobbying states to restrict access to biosimilars”
PharmaTimes “The big drug companies are targeting generic versions of such important brands as Humira [adalimumab] and Enbrel [etanercept], which treat rheumatoid arthritis, and Herceptin [trastuzumab], Avastin [bevacizumab] and Rituxan [rituximab], which target … |
USP sets up three new expert committees for its medicines compendiumpharmabiz.comAlso recently authorised is a monograph for rituximab, a monoclonal antibody used in the treatment of lymphoma, rheumatoid arthritis and other autoimmune disorders. This m…
Monoclonal Antibody Industry 2013 Global and China Market Analysis in New …Genetic Engineering News (press release)In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Ri…
Cord blood transplantation may cause fatal autoimmune diseaseHealioSteroids, rituximab (Rituxan, Genentech) and cyclosporine were the drugs most frequently used to treat hematological diseases. At a median follow-up of 26 months (range, 2 to 91 months)…
Speed of cancer drug administration increasedNursing TimesPatients diagnosed with follicular non-Hodgkin lymphoma (NHL), previously had rituximab administered via an intravenous drip. But the trial at Southampton General Hospital can now deliver a two-…